Get started
BioVersys AGBioVersys AGBioVersys AG

BioVersys AG

No trades
No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsETFs
Full chart
Full chart

Compare with BioVersys AG



Key stats


Market capitalization
‪167.75 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.5 CHF
Net income (FY)
‪−21.83 M‬ CHF
Revenue (FY)
‪800.00 K‬ CHF
Shares float
‪4.46 M‬
Beta (1Y)
−0.40

Latest earnings


Last report date
Sep 9, 2026
Report period
H1 2026
EPS
−2.66 CHF
Revenue
‪2.00 M‬ CHF

Employees


Employees (FY)
33
Revenue / Employee (1Y)
‪24.24 K‬ CHF
Net income / Employee (1Y)
‪−661.52 K‬ CHF

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Marc Gitzinger
Website
bioversys.com
Headquarters
Basel
Founded
2008
IPO date
Feb 7, 2025
ISIN
CH0210362643
FIGI
BBG01RXCPP94
Identifiers
ISIN CH0210362643
BioVersys AG is a clinical stage biopharmaceutical company, which engages in identifying, development, and commercializing novel antibacterial products for infections caused by multi-drug resistant (MDR) bacteria. It is involved in the research and development programs that address nosocomial infections of Acinetobacter baumannii and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


CHSPI
iShares Core SPI(R) ETF (CH)
Weight0.01%
Market value‪537.44 K‬
SPIA
UBS ETF (CH) - SPI (R) Units -CHF acc-
Weight0.01%
Market value‪158.39 K‬
SPICHA
UBS ETF (CHF) - UBS Core SPI(R) ETF Anteile CHF dis
Weight0.01%
Market value‪158.39 K‬
SPIEXT
UBS SPI(R) Extra ETF Units -CHF Acc-
Weight0.03%
Market value‪55.92 K‬

Explore more ETFs 

Frequently asked questions


The current price of BIOV is 26.6 CHF — it has increased by 1.78% in the past 24 hours. Watch BioVersys AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BioVersys AG stocks are traded under the ticker BIOV.
BIOV stock has risen by 6.32% compared to the previous week, the month change is a 10.00% rise, over the last year BioVersys AG has showed a −16.09% decrease.
We've gathered analysts' opinions on BioVersys AG future price: according to them, BIOV price has a max estimate of 100.00 CHF and a min estimate of 40.00 CHF. Watch BIOV chart and read a more detailed BioVersys AG stock forecast: see what analysts think of BioVersys AG and suggest that you do with its stocks.
BIOV reached its all-time high on Feb 7, 2025 with the price of 37.0 CHF, and its all-time low was 21.2 CHF and was reached on Nov 28, 2025. View more price dynamics on BIOV chart.
See other stocks reaching their highest and lowest prices.
BIOV stock is 7.52% volatile and has beta coefficient of −0.40. Track BioVersys AG stock price on the chart and check out the list of the most volatile stocks — is BioVersys AG there?
Today BioVersys AG has the market capitalization of ‪167.75 M‬, it has increased by 5.93% over the last week.
Yes, you can track BioVersys AG financials in yearly and quarterly reports right on TradingView.
BioVersys AG is going to release the next earnings report on Mar 31, 2027. Keep track of upcoming events with our Earnings Calendar.
BIOV earnings for the last half-year are −2.66 CHF per share, whereas the estimation was −2.00 CHF, resulting in a −33.00% surprise. The estimated earnings for the next half-year are −2.95 CHF per share. See more details about BioVersys AG earnings.
BioVersys AG revenue for the last half-year amounts to ‪2.00 M‬ CHF, despite the estimated figure of ‪1.30 M‬ CHF. In the next half-year revenue is expected to reach ‪700.00 K‬ CHF.
BIOV net income for the last half-year is ‪−15.59 M‬ CHF, while the previous report showed ‪−10.82 M‬ CHF of net income which accounts for 0.00% change. Track more BioVersys AG financial stats to get the full picture.
No, BIOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 21, 2026, the company has 33 employees. See our rating of the largest employees — is BioVersys AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioVersys AG EBITDA is ‪−27.93 M‬ CHF, and current EBITDA margin is ‪−2.77 K‬%. See more stats in BioVersys AG financial statements.
Like other stocks, BIOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioVersys AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioVersys AG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioVersys AG stock shows the neutral signal. See more of BioVersys AG technicals for a more comprehensive analysis.